CBLI: Cleveland BioLabs, Inc. - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

Cleveland BioLabs, Inc.

NASDAQ:CBLI

SummaryFactSheetFinancial
Notice
Stock data is unavailable or the company’s delisted.
Price
$3.27
Loss Chance
58.4%
0.09JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Related
United States Commodity Index Funds Trust - United States Copper Index Fund
NYSE:CPER
3.32
$20.84
38.04%
Guggenheim Strategic Opportunities Fund
NYSE:GOF
4.18
$17.02
14.82%
iShares Trust - iShares Biotechnology ETF
NASDAQ:IBB
3.81
$127.76
> 1,000%
iShares Trust - iShares Core S&P Small-Cap ETF
NYSE:IJR
4.26
$94.10
651.86%
iShares Trust - iShares Global Healthcare ETF
NYSE:IXJ
3.77
$94.84
428.08%
Jitta Factors
Growth Opportunity (18)
Recent Business Performance (0)
Financial Strength (32)
Return to Shareholders (0)
Competitive Advantage (6)
Jitta Signs
Recent Business PerformanceEarning Growth Last Quarter (YoY)
Revenue and EarningEarning loss detected in 2020
Operating MarginDeclined
Recent Business PerformanceEarning decline 9.06% in the last year
CapExVery High
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
0.09
100.00%
2.34
229.72%
2.34
229.72%
3.32
38.04%
4.18
14.82%
3.81
> 1,000%
COMPANY DESCRIPTION
As of July 27, 2021, Cleveland BioLabs, Inc. was acquired by Cytocom, Inc., in a reverse merger transaction. Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and immuno-oncology. The company’s product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand; and CBL0137, a small molecule with a multi-targeted mechanism for the treatment of various types of cancer. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, Rusnano, and Everon Biosciences. The company was incorporated in 2003 and is headquartered in Buffalo, New York.
www.cbiolabs.com
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.